The SLAMF3 rs509749 polymorphism correlates with malignant potential in multiple myeloma.

doi:10.1016/j.exphem.2020.08.006

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The SLAMF3 rs509749 polymorphism correlates with malignant potential in multiple myeloma.

Experimental hematology - 1 Oct 2020

Ishibashi Mariko, Sunakawa-Kii Mika, Kaito Yuta, Kinoshita Ryosuke, Asayama Toshio, Kuribayashi Yasuko, Inokuchi Koiti, Morita Rimpei, Tamura Hideto

Abstract excerpt

The signaling lymphocytic activation molecule family 3 (SLAMF3) is highly expressed on plasma cells from patients with multiple myeloma (MM) and induces high malignant potential by ERK signaling mediated via the interaction with adaptor proteins SHP2 and GRB2. This study focused on the single-nucleotide polymorphism (SNP) of the SLAMF3 gene (rs509749, 1804A>G, M602V) in MM. The SNP G allele was a major type, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Japan

Share to MAP Kinase Signaling System

Share to Mice

Share to Multiple Myeloma

Share to Neoplasm Proteins

Share to Survival Rate

Source

Open in PubMed

Identifiers

PMID: 32818503
DOI: 10.1016/j.exphem.2020.08.006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The SLAMF3 rs509749 polymorphism correlates with malignant potential in multiple myeloma.PMID 32818503Read ↗

SLAMF3-Mediated Signaling via ERK Pathway Activation Promotes Aggressive Phenotypic Behaviors in Multiple Myeloma.Semantic proximity Read ↗

Identification of mutation gene prognostic biomarker in multiple myeloma through gene panel exome sequencing and transcriptome analysis in Chinese population.Semantic proximity Read ↗

Association between BCL2 interacting protein 3 like (BNIP3L) genetic polymorphisms and the risk of multiple myeloma in China.Semantic proximity Read ↗

Fine Mapping of MHC Region Identifies Novel Susceptibility Loci in Multiple Myeloma When Comparing With Its Precursor Monoclonal Gammopathy of Unknown Significance.Semantic proximity Read ↗

Common gene variants within 3'-untranslated regions as modulators of multiple myeloma risk and survival.Semantic proximity Read ↗

Single‐cell transcriptome profiling reveals the key role of ZNF683 in natural killer cell exhaustion in multiple myelomaSemantic proximity Read ↗

Gene Expression and Clinical Relevance Analysis of ALG3 as an Adverse Prognosis Biomaker in Multiple Myeloma Based on Oncomine Database and CCLE DatabaseSemantic proximity Read ↗

Variations in suppressor molecule ctla-4 gene are related to susceptibility to multiple myeloma in a polish population.Semantic proximity Read ↗

Associations of VEGF and VEGFR2 polymorphisms with increased risk and aggressiveness of multiple myeloma.Semantic proximity Read ↗

The miRNA 196a2 rs11614913 variant has prognostic impact on Turkish patients with multiple myeloma.Semantic proximity Read ↗

Significance of a Tumor Microenvironment-Mediated P65-miR-30a-5p-BCL2L11 Amplification Loop in Multiple MyelomaSemantic proximity Read ↗

The TT Genotype of the KIAA1524 rs2278911 Polymorphism Is Associated with Poor Prognosis in Multiple Myeloma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.